Shanghai Henlius Biotech Inc. has announced the commencement of a new clinical trial involving their drug HANSIZHUANG (serplulimab injection) in Japan. In a recent voluntary announcement, the company disclosed that the first patient has been dosed in a bridging study of HANSIZHUANG in combination with chemotherapy (carboplatin-etoposide) for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). This trial marks a significant step in the company's efforts to expand the application of HANSIZHUANG in international markets. The results of this study have not yet been presented and are anticipated to be shared in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.